Special Topics Homepage
-
Trials Show Promise for New Agents to Treat COPD
Several trial results for the treatment of COPD were shared at the 2023 International Conference. Gerard J. Criner, MD, and David M. Mannino III, MD, discussed findings from the BOREAS trial, expectations from the ongoing NOTUS trial, and data from the ENHANCE-1 and ENHANCE-2 studies.
-
Ongoing Trials, Genetic Breakthroughs Pave the Way for Progress in Bronchiectasis
Timothy R. Aksamit, MD, FCCP, and Mark Metersky, MD, FCCP, comment on updates from multiple studies making headway in treating bronchiectasis. These trials, presented at the ATS 2023 International Conference, reflect research focusing on the three pillars of the disease: infection, inflammation, and mucociliary milieu. The trials included phase three of PROMIS II and phase…
-
New in Bronchiectasis: Advanced Understanding of Disease
The latest advancements in the understanding of the epidemiology, pathophysiology, and therapies of bronchiectasis will be highlighted in the ATS 2023 International Conference scientific program. Timothy R. Aksamit, MD, and Mark Metersky, MD, preview the hot topics of discussion among bronchiectasis specialists right now.
-
New in COPD: Early Disease and Classification Considerations
David M. Mannino III, MD, provides expert perspective on the important dialogue taking place among COPD specialists and what these respiratory health professionals can expect from the ATS 2023 International Conference in Washington, DC, this May.
-
International Conference Debut: Four Respiratory Societies Join to Discuss COPD in the Americas
The Respiratory Societies of the Americas session will debut at the ATS 2023 International Conference with a focus on COPD, challenges to accessing medicine for this disease, and the impact on health policies throughout the Americas.